Cargando…

Complication of coronavirus disease 2019 during remission induction therapy against anti-MDA5 antibody-positive dermatomyositis

Detalles Bibliográficos
Autores principales: Kogami, Masahiro, Suzuki, Satoshi, Nanjo, Yuta, Ikeda, Keigo, Tamura, Naoto, Sasaki, Shinichi, Morimoto, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717435/
https://www.ncbi.nlm.nih.gov/pubmed/33336141
http://dx.doi.org/10.1093/rap/rkaa068
_version_ 1783619311000092672
author Kogami, Masahiro
Suzuki, Satoshi
Nanjo, Yuta
Ikeda, Keigo
Tamura, Naoto
Sasaki, Shinichi
Morimoto, Shinji
author_facet Kogami, Masahiro
Suzuki, Satoshi
Nanjo, Yuta
Ikeda, Keigo
Tamura, Naoto
Sasaki, Shinichi
Morimoto, Shinji
author_sort Kogami, Masahiro
collection PubMed
description
format Online
Article
Text
id pubmed-7717435
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77174352020-12-09 Complication of coronavirus disease 2019 during remission induction therapy against anti-MDA5 antibody-positive dermatomyositis Kogami, Masahiro Suzuki, Satoshi Nanjo, Yuta Ikeda, Keigo Tamura, Naoto Sasaki, Shinichi Morimoto, Shinji Rheumatol Adv Pract Letter to the Editor (Case report) Oxford University Press 2020-11-17 /pmc/articles/PMC7717435/ /pubmed/33336141 http://dx.doi.org/10.1093/rap/rkaa068 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Letter to the Editor (Case report)
Kogami, Masahiro
Suzuki, Satoshi
Nanjo, Yuta
Ikeda, Keigo
Tamura, Naoto
Sasaki, Shinichi
Morimoto, Shinji
Complication of coronavirus disease 2019 during remission induction therapy against anti-MDA5 antibody-positive dermatomyositis
title Complication of coronavirus disease 2019 during remission induction therapy against anti-MDA5 antibody-positive dermatomyositis
title_full Complication of coronavirus disease 2019 during remission induction therapy against anti-MDA5 antibody-positive dermatomyositis
title_fullStr Complication of coronavirus disease 2019 during remission induction therapy against anti-MDA5 antibody-positive dermatomyositis
title_full_unstemmed Complication of coronavirus disease 2019 during remission induction therapy against anti-MDA5 antibody-positive dermatomyositis
title_short Complication of coronavirus disease 2019 during remission induction therapy against anti-MDA5 antibody-positive dermatomyositis
title_sort complication of coronavirus disease 2019 during remission induction therapy against anti-mda5 antibody-positive dermatomyositis
topic Letter to the Editor (Case report)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717435/
https://www.ncbi.nlm.nih.gov/pubmed/33336141
http://dx.doi.org/10.1093/rap/rkaa068
work_keys_str_mv AT kogamimasahiro complicationofcoronavirusdisease2019duringremissioninductiontherapyagainstantimda5antibodypositivedermatomyositis
AT suzukisatoshi complicationofcoronavirusdisease2019duringremissioninductiontherapyagainstantimda5antibodypositivedermatomyositis
AT nanjoyuta complicationofcoronavirusdisease2019duringremissioninductiontherapyagainstantimda5antibodypositivedermatomyositis
AT ikedakeigo complicationofcoronavirusdisease2019duringremissioninductiontherapyagainstantimda5antibodypositivedermatomyositis
AT tamuranaoto complicationofcoronavirusdisease2019duringremissioninductiontherapyagainstantimda5antibodypositivedermatomyositis
AT sasakishinichi complicationofcoronavirusdisease2019duringremissioninductiontherapyagainstantimda5antibodypositivedermatomyositis
AT morimotoshinji complicationofcoronavirusdisease2019duringremissioninductiontherapyagainstantimda5antibodypositivedermatomyositis